Bovine cartilage is used to prevent and treat cancer and treat HIV/AIDS; BioAnue Cartilage is administered orally. Several studies suggest bovine cartilage has antitumor and immunoregulatory effects.
The therapeutic potential of various types of cartilage have been studied for more than 40 years. The first reported use of bovine cartilage to treat a person with cancer was in 1972. John F. Prudden, MD, a New York surgeon, treated 31 patients with various types of cancer over several years. He published the results of this treatment in 1985. The report showed a high response rate. Allopathic medicine has been trying to discredit his work and thus hide this natural anti-cancer substance.
Cancer is the second most common cause of death in America. In fact 1/3 of the 1,467,180 cases diagnosed this year will result in needless death.
- Ruth from WV:
- Bonnie from OH:
I had a tumor in my breast and was scheduled for surgery when I began taking the TumorX Protocol along with BioAnue Bovine Cartilage. After three weeks of using the products I went in for my surgery. My surgeon removed a dead tumor. In the post op room he told me that mine were the best margins he had ever seen and whatever I was doing to keep it up.
When I was diagnosed with breast cancer I desperately wanted to take a natural approach to curing myself. I found the TumorX Protocol and decided that I had nothing to lose so I ordered and began taking the products. One of the products was BioAnue Bovine Cartilage. The tumor stop growing and actually shrank after only a short time on the products. The tumor is now completely dead!!
Science Demonstrates Cartilage Success
Here is a list of cancers that have been tested and shown a positive response to Bovine Cartilage:
Interestingly, cartilage research has also shown success in the most difficult region of the body to treat, i.e., the brain.2 A pre-clinical study published in the Proceedings of the American Society for Clinical Oncology by Berger et al., states that a 61% decrease in tumor volume was shown when mice were “subcutaneously grafted with human glioblastoma cells." When the cells were “inoculated into the brains of the animals” new blood vessel growth to the cell was stopped by 50%.2
Emerging science has shown that cartilage is effective in treating breast cancer. A pre-clinical trial published in Semin Oncology by Falardeau et al., states that oral administration of an extract derived from cartilage showed a significant reduction in tumor volume of mice that had been grafted with breast cancer cells.3
A study published in Journal of Biological Response Modifiers by Durie et al. states that 31 patients given oral doses of cartilage extracts showed a 90% success rate.4
Liu et al. published a study in Cancer Research that has shown that an extract from cartilage was “able to block the formation of tumor nodules in the lungs of mice” that were given lung carcinoma cells.5
Durie et al. states in Journal of Biological Response Modifiers that pre-clinical trials have shown that “high dose continuous exposure” to cartilage extract has proven successful in pancreatic cancer specimens.6
A study published in Annals of Oncology by Batist et al., reports that high doses of cartilage extract increases the survival time of patients with renal cell carcinoma.7 The study also reports that the extract showed no adverse reactions when administered at high doses.7
In fact, all cancers tested to date have shown a positive response when taken appropriately.
Cartilage demonstrates life saving potential; the writer believes that its effectiveness will extend to all cancers types.
Ideally, cartilage should be used in conjunction with other anti-cancer nutrients that have demonstrated the ability to kill cancer cells.
TumorX Brand products aid in the structure and function of the body; this allows deficiency induced diseases such as cancer, heart disease, diabetes and Alzheimer’s, just to name a few, to be reversed. Create better health with the TumorX supplement line of vitamins, minerals, herbs and enzymes.
1. American Cancer Society, Inc. No. 500808 page 1-2
2. Berger et al., Proc Am Soc Clin Oncol 20:2001(abstr 397)
3. Falardeau et al. Semin Oncol. 2001 Dec; 28(6):620-5
4. Durie et al. J Biol Response Mod. 1985 Dec;4(6):551-84
5. Liu, N et al., Cancer Research 61, 1022-1028, February 1, 2001.
6. Durie et al., J. Biol Response Mod. 1985 Dec;4(6):590-5
7. Batist et al., Ann Oncol. 2002 Aug;13(8):1259-63